Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of delta-9-tetrahydrocannabinol (THC), the primary psychoactive cannabinoid in cannabis, and d-limonene, a terpene found abundantly in citrus fruits and cannabis. Recent clinical studies have demonstrated that co-administration of vaporized THC with d-limonene significantly reduces subjective feelings of anxiety and paranoia commonly induced by THC alone. The anxiolytic effect is dose-dependent on d-limonene, with higher doses providing greater reduction in anxiety symptoms. Importantly, the addition of d-limonene does not alter other cognitive or physiological effects of THC nor its pharmacokinetics. This combination supports the "entourage effect" theory—where non-cannabinoid constituents modulate cannabinoid activity—and may increase the therapeutic index for THC by making it more tolerable for sensitive individuals or those using it therapeutically[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thc + limonene.